Freenome Files Amended 8-K with First Post-Merger Financials and Pro Forma Data
FRNM sits 17% above its 52-week low of $9.95.
Summary
Freenome's amended 8-K provides first-time financial statements and pro forma data for its business combination, revealing a $132.6M H1 net loss, $102M cash, and a $100M milestone payment from Exact Sciences.
Key Events · M&A and Partnerships · FRNM
-
First Post-Merger Financials Filed
Freenome Holdings reported a net loss of $132.6 million for the six months ended June 30, 2026, with cash and marketable securities of $102.0 million and an accumulated deficit of $1.5 billion.
-
Pro Forma Capitalization Disclosed
The pro forma combined company has 107,446,814 shares outstanding, with Freenome equity holders owning 63.4%, PIPE investors 22.3%, and Roche note holders 6.0%.
-
$100M Milestone Payment Earned
Following FDA approval of SimpleScreen CRC, Freenome will receive a $100.0 million milestone payment from Exact Sciences under the collaboration agreement.
-
Cash Runway Extended to 2028
Management states that current cash plus the $100M milestone payment and $295.5M net proceeds from the business combination should fund operations through 2028.
Analysis · FRNM · Industrial Applications And Services
This amendment provides the first detailed financial statements for Freenome Holdings as of June 30, 2026, and pro forma combined financials for the business combination with Perceptive Capital Solutions Corp. The financials reveal a net loss of $132.6 million for the first half of 2026, cash and marketable securities of $102.0 million, and an accumulated deficit of $1.5 billion. The pro forma data shows a post-combination capitalization of 107.4 million shares and net proceeds of $295.5 million. Management also discloses a $100.0 million milestone payment earned from Exact Sciences following FDA approval of SimpleScreen CRC, and states that current cash plus the milestone payment should fund operations through 2028. This is the first time investors can assess the combined company's financial position and runway.
At the time of this filing, FRNM was trading at $11.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.95 to $14.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.